Disease · MONDO_0001684

exocrine pancreatic insufficiency

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. exocrine pancreatic insufficiency. Diseases, record MONDO_0001684. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001684

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: exocrine pancreatic insufficiency; Open Targets
Open Targets ID: MONDO_0001684; Open Targets
Disease Ontology: DOID:13316; Disease Ontology
MeSH: D010188; MeSH
NCI Thesaurus: C84316; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 5 drugs, from PMDA; Open Targets

Drugs5

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PANCRELIPASE	CHEMBL2108074	Enzyme	Approval	PMDA	27	26	21	Drugs and targets
PANCREATIN	CHEMBL2108073		Phase 3	ClinicalTrials.gov	8	8	5	Drugs and targets
LIPROTAMASE	CHEMBL2108703	Enzyme	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
BUCELIPASE ALFA	CHEMBL2108297	Enzyme	Phase 3	TTD	1	0	0	Drugs and targets
MS-1819	CHEMBL4298049		Phase 2	ClinicalTrials.gov	5	4	4	Drugs and targets

Targets0

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

None in this release.

Trials36

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 7 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02279498	SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis	Phase 3	128	2018-08-14	Exocrine Pancreatic Insufficiency, Cystic Fibrosis	LIPROTAMASE, PANCRELIPASE	Its record names the disease	ClinicalTrials.gov
NCT02415959	Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis	Phase 2	70	2016-02-17	Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis	PANCRELIPASE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00414908	A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy	Phase 3	52	2009-09-16	Chronic Pancreatitis, Pancreatectomy, Pancreatic Exocrine Insufficiency	PANCRELIPASE	Its record names the disease	ClinicalTrials.gov
NCT00559364	Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea	Phase 3	50	2014-03-12	Exocrine Pancreatic Insufficiency, Chronic Pancreatitis, Pancreatectomy	PANCRELIPASE	Its record names the disease	ClinicalTrials.gov
NCT02137382	A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis	Phase 3	41	2015-11-27	Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis	PANCREATIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT03746483	OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis	Phase 2	41	2022-06-06	Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)	MS-1819	Its record names the disease	ClinicalTrials.gov
NCT00662675	A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency	Phase 3	40	2010-03-17	Exocrine Pancreatic Insufficiency, Steatorrhea, Malabsorption Syndromes, Cystic Fibrosis	PANCRELIPASE	Its record names the disease	ClinicalTrials.gov
NCT01747330	Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency	Phase 3	40	2014-07-15	Pancreatic Exocrine Insufficiency	PANCREATIN	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT03924947	A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis	Phase 4	36	2023-09-28	Cystic Fibrosis	PANCRELIPASE	Its record names the disease	ClinicalTrials.gov
NCT00510484	Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis	Phase 3	35	2009-07-20	Cystic Fibrosis	PANCRELIPASE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 36

See all 36 trials

Comparisons in its trials12

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Liprotamase vs Porcine (Pig) PERT: deaths from any cause	0 of 65	0 of 63	128	NCT02279498	Trial comparisons
Liprotamase vs Porcine (Pig) PERT: serious adverse events	7 of 65	6 of 63	128	NCT02279498	Trial comparisons
Creon® vs Creon N: serious adverse events	0 of 39	0 of 41	80	NCT02137382	Trial comparisons
MS1819 vs PERT: deaths from any cause	0 of 40	0 of 38	78	NCT03746483	Trial comparisons
MS1819 vs PERT: serious adverse events	0 of 40	0 of 38	78	NCT03746483	Trial comparisons
EUR-1008 (APT-1008) vs Placebo: serious adverse events	2 of 34	0 of 32	66	NCT00297167	Trial comparisons
Pancrelipase vs Placebo: serious adverse events	0 of 32	0 of 31	63	NCT00510484	Trial comparisons
Viokase® vs Placebo: serious adverse events	2 of 30	0 of 20	50	NCT00559364	Trial comparisons
PANCREASE MT vs Placebo: serious adverse events	0 of 20	0 of 20	40	NCT00662675	Trial comparisons
Pancrelipase vs Placebo: serious adverse events	0 of 17	0 of 16	33	NCT00690820	Trial comparisons

1 to 10 of 12

See all 12 comparisons in its trials

Papers from its trials7

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
20171415	RESULT	1	PubMed
19815466	RESULT	1	PubMed
32761612	DERIVED	4	PubMed
27013382	DERIVED	1	PubMed
25066363	DERIVED	1	PubMed
21681115	DERIVED	1	PubMed
19683970	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001684

GET https://conductscience.org/api/diseases/v1/MONDO_0001684/trials?page=2

API reference For AI assistants